Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7707764 | 0.81 | NFKB1 (0.33) | — | |
| SCHEMBL28130115 | 0.80 | CYP2D6 (0.32) | CYP2D6 | |
| SCHEMBL4974374 | 0.78 | — | — | |
| SCHEMBL22508726 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL15270046 | 0.75 | — | — | |
| SCHEMBL22855339 | 0.75 | — | — | |
| SCHEMBL196566 | 0.75 | — | — | |
| SCHEMBL3175803 | 0.75 | — | — | |
| SCHEMBL15289539 | 0.73 | — | — | |
| SCHEMBL35812 | 0.72 | CYP2D6 (0.44) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114025844-B | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114025844-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| EP-2727920-B1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORP (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8841456-B2 | 1,5-naphthyridine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140142302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2014-05-22 | — | — | US | disclosed |
| EP-1951709-A2 | IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| WO-2007058862-A2 | IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1720856-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7074828-B2 | Compounds that stimulate glucose utilization and methods of use | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2006-07-11 | — | — | US | disclosed |
| EP-1568684-A1 | para-phenylenediamines carrying an alkoxy group, dye composition, preparation methods and their use | L'OREAL (FR) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | CYP2D6 1318/4885 |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | CYP2D6 2414/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | CYP2D6 2970/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | CYP2D6 1891/4885 |
| US-20140142302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF | NRAS, RAF1, KRAS | CYP2D6 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.